CN107793389B - 手性四氢吡喃衍生物及其制备与用途 - Google Patents
手性四氢吡喃衍生物及其制备与用途 Download PDFInfo
- Publication number
- CN107793389B CN107793389B CN201610802433.8A CN201610802433A CN107793389B CN 107793389 B CN107793389 B CN 107793389B CN 201610802433 A CN201610802433 A CN 201610802433A CN 107793389 B CN107793389 B CN 107793389B
- Authority
- CN
- China
- Prior art keywords
- compound
- reaction
- generate
- reducing agent
- carrying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 150000003527 tetrahydropyrans Chemical class 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 113
- 238000000034 method Methods 0.000 claims abstract description 19
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract description 6
- 125000004434 sulfur atom Chemical group 0.000 claims abstract description 6
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims abstract description 3
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 3
- 125000003118 aryl group Chemical group 0.000 claims abstract description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 3
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 3
- 150000002367 halogens Chemical class 0.000 claims abstract description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 169
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 73
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 72
- 239000002904 solvent Substances 0.000 claims description 69
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 64
- 238000006243 chemical reaction Methods 0.000 claims description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 49
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 45
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 43
- 238000007254 oxidation reaction Methods 0.000 claims description 43
- -1 sodium triacetoxyborohydride Chemical compound 0.000 claims description 42
- 239000003638 chemical reducing agent Substances 0.000 claims description 39
- 238000006268 reductive amination reaction Methods 0.000 claims description 39
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 30
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 238000010511 deprotection reaction Methods 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 19
- 238000006722 reduction reaction Methods 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 18
- 238000005917 acylation reaction Methods 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 16
- 235000011054 acetic acid Nutrition 0.000 claims description 14
- 238000007142 ring opening reaction Methods 0.000 claims description 14
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims description 13
- 229940125846 compound 25 Drugs 0.000 claims description 13
- 238000006482 condensation reaction Methods 0.000 claims description 13
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical group [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 13
- 238000006467 substitution reaction Methods 0.000 claims description 13
- 239000004593 Epoxy Substances 0.000 claims description 12
- 150000001412 amines Chemical class 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical group [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims description 12
- 239000012321 sodium triacetoxyborohydride Substances 0.000 claims description 12
- 238000005984 hydrogenation reaction Methods 0.000 claims description 9
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 claims description 8
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 8
- 229940125904 compound 1 Drugs 0.000 claims description 8
- 235000019253 formic acid Nutrition 0.000 claims description 8
- MVXAKOGJWVQPKC-UHFFFAOYSA-N 5-(3-ethynyl-5-fluorophenyl)-2-pyridin-2-yl-4,6,7,8-tetrahydro-[1,3]oxazolo[4,5-c]azepine Chemical compound FC1=CC(C#C)=CC(N2CC=3N=C(OC=3CCC2)C=2N=CC=CC=2)=C1 MVXAKOGJWVQPKC-UHFFFAOYSA-N 0.000 claims description 7
- 150000004678 hydrides Chemical class 0.000 claims description 7
- JYRWUSXRTGACLY-UHFFFAOYSA-N tert-butyl 4-[[3-(4-methylsulfonylphenyl)-[1,2]oxazolo[4,5-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=NC=NC2=C1ON=C2C1=CC=C(S(C)(=O)=O)C=C1 JYRWUSXRTGACLY-UHFFFAOYSA-N 0.000 claims description 7
- 150000004820 halides Chemical class 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 230000003647 oxidation Effects 0.000 claims description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 claims description 5
- 229940125833 compound 23 Drugs 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 150000002596 lactones Chemical class 0.000 claims description 5
- 230000000269 nucleophilic effect Effects 0.000 claims description 5
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims description 5
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 claims description 5
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims description 4
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims description 4
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 claims description 4
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 claims description 4
- 229940126657 Compound 17 Drugs 0.000 claims description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 4
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims description 4
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 claims description 4
- 229940126543 compound 14 Drugs 0.000 claims description 4
- 229940125758 compound 15 Drugs 0.000 claims description 4
- 229940126142 compound 16 Drugs 0.000 claims description 4
- 229940125810 compound 20 Drugs 0.000 claims description 4
- 229940125961 compound 24 Drugs 0.000 claims description 4
- 229940125851 compound 27 Drugs 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims description 4
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 238000005935 nucleophilic addition reaction Methods 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 230000001681 protective effect Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 235000009518 sodium iodide Nutrition 0.000 claims description 4
- 238000011916 stereoselective reduction Methods 0.000 claims description 4
- LAJAFFLJAJMYLK-CVOKMOJFSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[[(7s)-4-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5h-benzo[7]annulen-3-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N1([C@H]2CCC3=CC=C(C(=C3CC2)OC)NC=2N=C(C(=CN=2)Cl)N[C@H]2[C@H]([C@@]3([H])C[C@@]2(C=C3)[H])C(N)=O)CCOCC1 LAJAFFLJAJMYLK-CVOKMOJFSA-N 0.000 claims description 3
- YRTFLDFDKPFNCJ-UHFFFAOYSA-N 1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-2-oxo-4-[3-(3-pyrrolidin-1-ylpropoxy)phenyl]-1,8-naphthyridin-3-yl]urea;dihydrochloride Chemical compound Cl.Cl.CC(C)C=1C=C(N)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C(C=1)=CC=CC=1OCCCN1CCCC1 YRTFLDFDKPFNCJ-UHFFFAOYSA-N 0.000 claims description 3
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 claims description 3
- HCLQARMRCPEALF-DNQXCXABSA-N 3-[[(2r)-2-[(1r)-2-[[1-(1-benzothiophen-2-yl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]pyrrolidin-1-yl]methyl]benzonitrile Chemical compound C([C@@H]1[C@H](O)CNC(C)(CC=2SC3=CC=CC=C3C=2)C)CCN1CC1=CC=CC(C#N)=C1 HCLQARMRCPEALF-DNQXCXABSA-N 0.000 claims description 3
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 150000001540 azides Chemical class 0.000 claims description 3
- AJRQIXBBIDPNGK-BVSLBCMMSA-N benzyl n-[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](C[C@H]1C(NCC1)=O)C(=O)C=1SC2=CC=CC=C2N=1)C(=O)OCC1=CC=CC=C1 AJRQIXBBIDPNGK-BVSLBCMMSA-N 0.000 claims description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 3
- OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical group [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000004280 Sodium formate Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 229910052760 oxygen Chemical group 0.000 claims description 2
- 239000001301 oxygen Chemical group 0.000 claims description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 claims description 2
- 235000019254 sodium formate Nutrition 0.000 claims description 2
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 claims description 2
- 239000004324 sodium propionate Substances 0.000 claims description 2
- 235000010334 sodium propionate Nutrition 0.000 claims description 2
- 229960003212 sodium propionate Drugs 0.000 claims description 2
- UYCAUPASBSROMS-AWQJXPNKSA-M sodium;2,2,2-trifluoroacetate Chemical compound [Na+].[O-][13C](=O)[13C](F)(F)F UYCAUPASBSROMS-AWQJXPNKSA-M 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 claims description 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims 2
- DAAXYQZSKBPJOX-FQEVSTJZSA-N (2S)-2-amino-3-[4-[5-[3-(4-hydroxyphenyl)-4-methoxyphenyl]-1,2,4-oxadiazol-3-yl]phenyl]propanoic acid Chemical compound COC1=C(C=C(C=C1)C2=NC(=NO2)C3=CC=C(C=C3)C[C@@H](C(=O)O)N)C4=CC=C(C=C4)O DAAXYQZSKBPJOX-FQEVSTJZSA-N 0.000 claims 2
- BCSHRERPHLTPEE-NRFANRHFSA-N 2-[[5-chloro-2-[[(6s)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5h-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1NC1=NC(NC=2C(=C3CCC[C@@H](CC3=CC=2)N2CCN(CCO)CC2)OC)=NC=C1Cl BCSHRERPHLTPEE-NRFANRHFSA-N 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 abstract description 5
- 239000003054 catalyst Substances 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 229910000510 noble metal Inorganic materials 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 49
- 230000035484 reaction time Effects 0.000 description 36
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- 229960001701 chloroform Drugs 0.000 description 29
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 28
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 21
- 239000012044 organic layer Substances 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- 239000000741 silica gel Substances 0.000 description 17
- 229910002027 silica gel Inorganic materials 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- 150000008282 halocarbons Chemical class 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- 229960000583 acetic acid Drugs 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 239000007800 oxidant agent Substances 0.000 description 14
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 13
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 12
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical group OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 230000001590 oxidative effect Effects 0.000 description 11
- 239000003377 acid catalyst Substances 0.000 description 10
- 239000003208 petroleum Substances 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 238000001035 drying Methods 0.000 description 9
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 9
- JOXIMZWYDAKGHI-UHFFFAOYSA-N p-toluenesulfonic acid Substances CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 9
- 238000010791 quenching Methods 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 9
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 8
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 8
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 8
- 239000000386 donor Substances 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 8
- 235000019345 sodium thiosulphate Nutrition 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical group C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- 239000002841 Lewis acid Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 6
- 239000000852 hydrogen donor Substances 0.000 description 6
- 239000011968 lewis acid catalyst Substances 0.000 description 6
- 150000007517 lewis acids Chemical class 0.000 description 6
- 239000012038 nucleophile Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- VEPTXBCIDSFGBF-UHFFFAOYSA-M tetrabutylazanium;fluoride;trihydrate Chemical group O.O.O.[F-].CCCC[N+](CCCC)(CCCC)CCCC VEPTXBCIDSFGBF-UHFFFAOYSA-M 0.000 description 6
- RXCVUHMIWHRLDF-HXUWFJFHSA-N 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one Chemical compound ClC1=C2CCN(C(C2=C(C(=C1)[C@@H](C1COC1)OC)Cl)=O)CC=1C(NC(=CC=1OC)C)=O RXCVUHMIWHRLDF-HXUWFJFHSA-N 0.000 description 5
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 5
- 239000000010 aprotic solvent Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000012280 lithium aluminium hydride Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 5
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical group ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical group SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 4
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical group [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000005708 Sodium hypochlorite Substances 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 4
- 229910052793 cadmium Inorganic materials 0.000 description 4
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 4
- YKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 description 4
- 229940126086 compound 21 Drugs 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 150000007529 inorganic bases Chemical class 0.000 description 4
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 4
- 229910052753 mercury Inorganic materials 0.000 description 4
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 4
- 239000012434 nucleophilic reagent Substances 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical group ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 4
- XCAQIUOFDMREBA-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonyl]carbamate Chemical compound CC(C)(C)OC(=O)NC(=O)OC(C)(C)C XCAQIUOFDMREBA-UHFFFAOYSA-N 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000006772 olefination reaction Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 125000005489 p-toluenesulfonic acid group Chemical group 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- RNOAOAWBMHREKO-QFIPXVFZSA-N (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C(C=C)(=O)N1CCC(CC1)[C@@H]1CCNC=2N1N=C(C=2C(=O)N)C1=CC=C(C=C1)OC1=CC=CC=C1 RNOAOAWBMHREKO-QFIPXVFZSA-N 0.000 description 2
- DPRJPRMZJGWLHY-HNGSOEQISA-N (e,3r,5s)-7-[5-(4-fluorophenyl)-3-propan-2-yl-1-pyrazin-2-ylpyrazol-4-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)/C=C/C=1C(C(C)C)=NN(C=2N=CC=NC=2)C=1C1=CC=C(F)C=C1 DPRJPRMZJGWLHY-HNGSOEQISA-N 0.000 description 2
- YAXWOADCWUUUNX-UHFFFAOYSA-N 1,2,2,3-tetramethylpiperidine Chemical compound CC1CCCN(C)C1(C)C YAXWOADCWUUUNX-UHFFFAOYSA-N 0.000 description 2
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 2
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 2
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-Tetramethylpiperidine Substances CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 2
- FBPINGSGHKXIQA-UHFFFAOYSA-N 2-amino-3-(2-carboxyethylsulfanyl)propanoic acid Chemical compound OC(=O)C(N)CSCCC(O)=O FBPINGSGHKXIQA-UHFFFAOYSA-N 0.000 description 2
- 229910000497 Amalgam Inorganic materials 0.000 description 2
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 2
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 2
- 229940073608 benzyl chloride Drugs 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 229910000011 cadmium carbonate Inorganic materials 0.000 description 2
- CXKCTMHTOKXKQT-UHFFFAOYSA-N cadmium oxide Inorganic materials [Cd]=O CXKCTMHTOKXKQT-UHFFFAOYSA-N 0.000 description 2
- GKDXQAKPHKQZSC-UHFFFAOYSA-L cadmium(2+);carbonate Chemical compound [Cd+2].[O-]C([O-])=O GKDXQAKPHKQZSC-UHFFFAOYSA-L 0.000 description 2
- CFEAAQFZALKQPA-UHFFFAOYSA-N cadmium(2+);oxygen(2-) Chemical compound [O-2].[Cd+2] CFEAAQFZALKQPA-UHFFFAOYSA-N 0.000 description 2
- 150000001728 carbonyl compounds Chemical class 0.000 description 2
- HERWQQFSESWGRK-UHFFFAOYSA-N chromium(6+) oxygen(2-) pyridin-1-ium chloride Chemical compound Cl.N1=CC=CC=C1.[O-2].[O-2].[O-2].[Cr+6] HERWQQFSESWGRK-UHFFFAOYSA-N 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- LJXTYJXBORAIHX-UHFFFAOYSA-N diethyl 2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1 LJXTYJXBORAIHX-UHFFFAOYSA-N 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- 238000006735 epoxidation reaction Methods 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- DQDCGTUHSVXZIS-UHFFFAOYSA-N iodobenzene;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.IC1=CC=CC=C1 DQDCGTUHSVXZIS-UHFFFAOYSA-N 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical group C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229960002523 mercuric chloride Drugs 0.000 description 2
- 229940101209 mercuric oxide Drugs 0.000 description 2
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 2
- MJGFBOZCAJSGQW-UHFFFAOYSA-N mercury sodium Chemical compound [Na].[Hg] MJGFBOZCAJSGQW-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- YRCHYHRCBXNYNU-UHFFFAOYSA-N n-[[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-(4-fluorophenyl)acetamide Chemical compound N1=CC(CNCCOC)=CC=C1C1=CC2=NC=CC(OC=3C(=CC(NC(=S)NC(=O)CC=4C=CC(F)=CC=4)=CC=3)F)=C2S1 YRCHYHRCBXNYNU-UHFFFAOYSA-N 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229910001023 sodium amalgam Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 229950009390 symclosene Drugs 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 238000009901 transfer hydrogenation reaction Methods 0.000 description 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical group CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- RHUYHJGZWVXEHW-UHFFFAOYSA-N 1,1-Dimethyhydrazine Chemical compound CN(C)N RHUYHJGZWVXEHW-UHFFFAOYSA-N 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- QMFJIJFIHIDENY-UHFFFAOYSA-N 1-Methyl-1,3-cyclohexadiene Chemical compound CC1=CC=CCC1 QMFJIJFIHIDENY-UHFFFAOYSA-N 0.000 description 1
- XCRCSPKQEDMVBO-UHFFFAOYSA-N 2-bromo-1,4-difluorobenzene Chemical compound FC1=CC=C(F)C(Br)=C1 XCRCSPKQEDMVBO-UHFFFAOYSA-N 0.000 description 1
- WLHCBQAPPJAULW-UHFFFAOYSA-N 4-methylbenzenethiol Chemical compound CC1=CC=C(S)C=C1 WLHCBQAPPJAULW-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical group CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- DIIWSYPKAJVXBV-UHFFFAOYSA-N Hantzch dihydropyridine Natural products CCOC(=O)C1=CC(C(=O)OCC)=C(C)N=C1C DIIWSYPKAJVXBV-UHFFFAOYSA-N 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- DSVGQVZAZSZEEX-UHFFFAOYSA-N [C].[Pt] Chemical compound [C].[Pt] DSVGQVZAZSZEEX-UHFFFAOYSA-N 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical group [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- GCSVCUMDOQKEMT-UHFFFAOYSA-N butan-1-amine;hydrofluoride Chemical compound [H+].[F-].CCCCN GCSVCUMDOQKEMT-UHFFFAOYSA-N 0.000 description 1
- JJNHBFYGCSOONU-UHFFFAOYSA-M carbanide;cyclopenta-1,3-diene;dimethylaluminum;titanium(4+);chloride Chemical compound [CH3-].[Ti+3]Cl.C[Al]C.C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 JJNHBFYGCSOONU-UHFFFAOYSA-M 0.000 description 1
- YNBJMIXWGPOBGE-UHFFFAOYSA-N carbanide;cyclopenta-1,3-diene;titanium(4+) Chemical compound [CH3-].[CH3-].[Ti+4].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 YNBJMIXWGPOBGE-UHFFFAOYSA-N 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- VTXVGVNLYGSIAR-UHFFFAOYSA-N decane-1-thiol Chemical compound CCCCCCCCCCS VTXVGVNLYGSIAR-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-KHWXYDKHSA-N methanesulfonyl chloride Chemical group C[35S](Cl)(=O)=O QARBMVPHQWIHKH-KHWXYDKHSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- VQSRKMNBWMHJKY-YTEVENLXSA-N n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]23[C@@H](CN(C2)C=2N=CC(F)=CN=2)CSC(N)=N3)=C1 VQSRKMNBWMHJKY-YTEVENLXSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229910003445 palladium oxide Inorganic materials 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- JQPTYAILLJKUCY-UHFFFAOYSA-N palladium(ii) oxide Chemical compound [O-2].[Pd+2] JQPTYAILLJKUCY-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920001843 polymethylhydrosiloxane Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical class OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明公开了一种式22所示的化合物,其中,R选自被卤素、C1‑C3烷基、C2‑C3链烯基中的一种或多种所取代的五到六元芳基、含1‑2个硫原子的五到六元杂芳基、被C1‑C3烷硫基取代的C1‑C3烷基或含1‑2个硫原子的5‑6元环烷基。本发明还公开了其制备方法及用途。其可实现多种新型四氢吡喃手性衍生物的合成,不涉及贵金属催化剂等原料,降低成本。
Description
技术领域
本发明属于化学合成领域,具体涉及四氢吡喃手性衍生物、其合成方法及其中间体。
技术背景
四氢吡喃手性衍生物常具有多种生物活性,例如化合物1是一种DPPIV抑制剂,可用于糖尿病治疗。发展四氢吡喃手性衍生物的新合成方法,例如化合物1,对相关的生物研究和药物开发具有较高价值。
已有多篇文献【1)Arroyo,I.;Krueger,D.;Chen,P.;Moment,A.;Biftu,T.;Sheen,F.;Zhang,Y.WO2013003249A1.2)Biftu,T.;Chen,P.;Cox,J.M.;Weber,A.E.US20100120863A1.3)Biftu,T.;Sinha-Roy,R.;Chen,P.;Qian,X.;Feng,D.;Kuethe,J.T.;Scapin,G.;Gao,Y.D.;Yan,Y.;Krueger,D.;Bak,A.;Eiermann,G.;He,J.;Cox,J.;Hicks,J.;Lyons,K.;He,H.;Salituro,G.;Tong,S.;Patel,S.;Doss,G.;Petrov,A.;Wu,J.;Xu,S.S.;Sewall,C.;Zhang,X.;Zhang,B.;Thornberry,N.A.;Weber,A.E.J.Med.Chem.2014,57,3205-3212.4)Zacuto,M.J.;Dunn,R.F.;Moment,A.J.;Janey,J.M.;Lieberman,D.;Sheen,F.;Bremeyer,N.;Scott,J.;Kuethe,J.T.;Tan,L.;Chen,Q.WO2013003250A1.】描述了化合物1的合成方法。其中一种代表性的方法是由亚胺2和炔丙醇衍生物3出发,经钌催化的不对称还原得中间体6,再经钌或铑催化的环合反应等得到中间体7,最后通过羟基化和氧化反应得羰基化合物9,再由羰基化合物9和杂环衍生物10出发,经还原胺化得中间体11,最后脱Boc得到化合物1。反应路线如下:
该方法使用多种贵金属催化剂以及昂贵的手性配体,存在路线改进的空间。
发明内容
本发明的目的在于提供一种可合成新型四氢吡喃手性衍生物的路线,也可用于制备化合物1。
本发明通过以下技术方案实现:
根据Fleet等报道的合成方法【Jones,N.A.;Jenkinson,S.F.;Soengas,R.;Fanefjord,M.;Wormald,M.R.;Dwek,R.A.;Kiran,G.P.;Devendar,R.;Takata,G.;Morimoto,K.;Izumori,K.;Fleet,G.W.J.Tetrahedron:Asymmetry 2007,18,774-786.】,从廉价的D-阿拉伯糖出发,可合成具有多种保护基的内酯12。结合多篇糖化学方法研究报道【1)Bessières,B.;Morin,C.The Journal of Organic Chemistry 2003,68,4100-4103.2)Jiang,S.;Rycroft,A.D.;Singh,G.;Wang,X.-Z.;Wu,Y.-L.Tetrahedron Letters 1998,39,3809-3812.3)Nicolaou,K.C.;Ohshima,T.;Hosokawa,S.;Van Delft,F.L.;Vourloumis,D.;Xu,J.Y.;Pfefferkorn,J.;Kim,S.J.Am.Chem.Soc.1998,120,8674-8680.】,内酯12的PG1是三甲基硅基、三乙基硅基、叔丁基二甲基硅基、叔丁基二苯基硅基或对甲氧基苄基等,PG2是苄叉基、对甲基苄叉基或丙叉基等。
申请人从内酯12出发,通过多步反应,合成了多种多手性取代四氢吡喃衍生物,其中涉及一个重要中间体,即式22所示的化合物,
R选自被卤素(例如,F、Cl、Br等)、C1-C3烷基、C2-C3链烯基中的一种或多种所取代的五到六元芳基、含1-2个硫原子的五到六元杂芳基、被C1-C3烷硫基取代的C1-C3烷基、或含1-2个硫原子的5-6元环烷基,优选为
本发明还提供了所述式22所示化合物的制备方法,其包括如下步骤:化合物20b与还原剂发生2,3-环氧开环反应,生成化合物22;
其中,所述还原剂选自卤化物还原剂或氢化物还原剂;
所述氢化物还原剂选自氰基硼氢化钠或三乙酰氧基硼氢化钠;所述卤化物还原剂选自碘化钠、碘化钾、碘化锂或四丁基碘化铵;
当还原剂为卤化物还原剂时,所述2,3-环氧开环反应需要在反应促进剂存在下进行,所述反应促进剂选自醋酸、甲酸、丙酸、或三氟乙酸;醋酸钠、甲酸钠、丙酸钠、或三氟乙酸钠。
所述2,3-环氧开环反应在溶剂中进行,所述溶剂选自丙酮、甲醇、乙醇、二氯甲烷、三氯甲烷、乙腈、TBME、DMF、水和THF中的一种或多种溶剂的混合物。
所述化合物20b可以由如下步骤制备:
(a)内酯12与金属盐13发生亲核加成反应,生成化合物14;
(b)化合物14与含有氢化硅结构的还原剂发生立体选择性还原反应,生成化合物15;
(c)化合物15发生2-O脱保护反应,生成化合物16;
(d)化合物16与酰化剂发生酰化反应,生成化合物17;
(e)化合物17发生3,4-O脱保护反应,脱除PG2保护基,生成化合物18;
(f)化合物18发生环氧化反应,生成化合物19;
(g)化合物19发生氧化反应,生成化合物20b;
其中,
R的定义同前;
M为Mg或Li;
PG1选自三甲基硅基、三乙基硅基、叔丁基二甲基硅基、叔丁基二苯基硅基、对甲氧基苄基或苄基;
PG2选自苄叉基、对甲基苄叉基或丙叉基;
LG选自对甲基苯磺酰基、甲磺酰基、苯磺酰基、咪唑磺酰基或三氟甲磺酰基。
其中,
步骤(a)中,
所述亲核加成反应在溶剂存在下进行;
所述溶剂可以是醚类、甲苯、己烷和二氯甲烷中的一种或多种的混合溶剂;所述醚类选自乙醚、TBME、异丙醚、2-甲基THF和THF中的一种或多种;所述溶剂优选为乙醚。
优选的,所述亲核试剂在和路易斯酸催化剂存在下进行,所述路易斯酸催化剂选自CuI、三氟甲磺酸亚铜(CuOTf)、CuCN、LiCl、CuBr、CuBr二甲硫醚配合物、三氟化硼乙醚或TMSCl等。
所述亲核加成反应的温度在-100摄氏度到-10摄氏度之间,反应时间为0.5小时至12小时。
步骤(b)中,
所述含有氢化硅结构的还原剂选自三乙基硅烷或聚甲基氢硅氧烷等;
所述立体选择性还原性反应在路易斯酸催化剂的存在下进行,所述路易斯酸催化剂选自三氟化硼乙醚或三氟甲磺酸三甲基硅酯(TMSOTf)等;
所述立体选择性还原性反应在有机溶剂中进行,有机溶剂选自二氯甲烷、三氯甲烷、乙腈、TBME和THF中的一种或多种溶剂的混合物;
所述立体选择性还原性反应的温度在-80摄氏度到+20摄氏度之间,反应时间为0.5小时至12小时;
步骤(c)中,
所述2-O脱保护反应在含氟试剂或氧化剂存在下进行;所述含氟试剂选自四丁基氟化铵三水合物(TBAF)、KHF2或KF等;所述氧化剂选自二氯二氰基苯醌(DDQ)等;
所述2-O脱保护反应的反应温度在-20摄氏度到+70摄氏度之间,反应时间为0.5小时至24小时。
步骤(d)中,
所述酰化剂选自对甲苯磺酰氯、甲磺酰氯、苯磺酰氯或三氟甲磺酸酐等;
所述酰化反应在缚酸剂存在下进行,所述缚酸剂选自三乙胺、DIPEA(N,N-二异丙基乙胺)或DBU(二氮杂二环,CAS:6674-22-2)等;
所述酰化反应在溶剂中进行,所述溶剂选自二氯甲烷、三氯甲烷、乙腈、TBME、DMF和THF中的一种或多种溶剂的混合物;
所述酰化反应的温度在-100摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
步骤(e)中,
所述3,4-O脱保护反应在对PG2保护基敏感的酸性物质存在下进行,所述对PG2保护基敏感的酸性物质选自对甲苯磺酸、樟脑磺酸、盐酸、醋酸、硫酸或三氟乙酸等,反应温度在-20摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
步骤(f)中,
所述环氧化反应在碱存在下进行,所述碱选自甲醇钠、乙醇钠或氢氧化钠等;
所述环氧化反在溶剂中进行,所述溶剂选自丙酮、甲醇、乙醇、二氯甲烷、三氯甲烷、乙腈、叔丁基甲基醚(TBME)、N,N-二甲基甲酰胺(DMF)、水和四氢呋喃(THF)中的一种或多种溶剂的混合物;
反应温度在-20摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
步骤(g)中,
所述氧化反应为基于二甲基亚砜的氧化反应、Dess-Martin氧化反应、PCC氧化反应或TEMPO催化的氧化反应。
当所述氧化反应是基于二甲基亚砜的氧化反应时,所述氧化反应以DMSO和活化剂为氧化剂,在有机碱的存在下,于卤代烃溶剂中,在-78摄氏度至+50摄氏度范围中进行,反应时间为0.5小时至12小时。所述卤代烃溶剂选自二氯甲烷、1,2-二氯乙烷、以及氯仿;所述活化剂选自草酰氯、吡啶-三氧化硫配合物、N-氯代丁二酰亚胺、醋酐、三氟乙酸酐等;所述有机碱选自三乙胺、二异丙基乙胺、DBU等。
当所述氧化反应是Dess-Martin氧化反应时,所述氧化反应以Dess-Martin试剂为氧化剂,于卤代烃或醚类溶剂中,在-20摄氏度至+50摄氏度范围中进行,反应时间为0.5小时至12小时。所述卤代烃溶剂选自二氯甲烷、1,2-二氯乙烷、以及氯仿;所述醚类烃溶剂选自THF、乙醚、叔丁基甲基醚等。
当所述氧化反应是PCC氧化时,所述氧化反应以三氧化铬吡啶盐酸盐为氧化剂,于卤代烃溶剂中,在-78摄氏度至+50摄氏度范围中进行,反应时间为0.5小时至12小时。所述卤代烃溶剂选自二氯甲烷、1,2-二氯乙烷、以及氯仿。
当所述氧化反应是TEMPO催化的氧化反应时,所述氧化反应以次氯酸钙、次氯酸钠、或三氯异氰尿酸为氧化剂,以四甲基哌啶氮氧化物(TEMPO)为催化剂于卤代烃溶剂中,在-78摄氏度至+50摄氏度范围中进行,反应时间为0.5小时至12小时。所述卤代烃溶剂选自二氯甲烷、1,2-二氯乙烷、以及氯仿。
其中,化合物19还可以发生取代反应生产化合物20a:
化合物19发生取代反应,生成化合物20a;
所述取代反应在O-硅烷化或烷基化试剂存在下进行,所述O-硅烷化或烷基化试剂选自叔丁基二甲基氯化硅(TBSCl)、叔丁基二苯基氯硅烷(TBDPSCl)、苄基氯(BnCl)或对甲氧基苯甲基氯(PMBCl);
所述取代反应在碱存在下进行,所述碱选自咪唑、三乙胺、DIPEA、钠氢、甲醇钠、乙醇钠或氢氧化钠等。
所述取代反应在非质子溶剂中进行,所述非质子溶剂选自二氯甲烷、乙二醇二甲醚、TBME、DMF、2-MeTHF和THF中的一种或多种溶剂的混合物。
所述取代反应的反应温度在-20摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
其中,化合物19还可以发生2,3‐环氧开环反应生产化合物21a:
化合物19与还原剂发生2,3‐环氧开环反应,生成化合物21a;
所述还原剂选自锂铝氢、三叔丁氧基锂铝氢、Red-Al或DIBAL-H等;
所述2,3-环氧开环反应在非质子溶剂中进行,所述非质子溶剂选自二氯甲烷、乙二醇二甲醚、TBME、DMF、2-MeTHF和THF中的一种或多种溶剂的混合物;
所述2,3-环氧开环反应的温度在-78摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
其中,化合物20a还可以发生2,3-环氧开环反应生产化合物21b:
化合物20a与还原剂发生2,3‐环氧开环反应,生成化合物21b;
所述还原剂选自锂铝氢、三叔丁氧基锂铝氢、Red-Al或DIBAL-H等;
所述2,3-环氧开环反应在非质子溶剂中进行,所述非质子溶剂选自二氯甲烷、乙二醇二甲醚、TBME、DMF、2-MeTHF和THF中的一种或多种溶剂的混合物;
所述2,3-环氧开环反应的温度在-78摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
本发明还提供了所述的式22所示化合物的用途,可用于制备化合物23a、23b或23c,反应式如下:
(a)式22所示化合物与X-H和Y-H发生缩合反应,生成化合物23a;或
(c)式22所示化合物发生烯烃化反应,生成化合物23c;
其中,
X、Y各自独立地选自乙硫基、甲硫基、乙氧基或甲氧基;
A、B各自独立地为硫或氧;
n为1、2或3。
其中,
步骤(a)中,
所述缩合反应在醇类亲核试剂或硫醇类亲核试剂存在下进行;所述醇类亲核试剂选自甲醇,或乙醇等;所述硫醇类亲核试剂选自甲硫醇,或乙硫醇等。
所述缩合反应在质子酸催化剂或路易斯酸催化剂存在下进行,所述质子酸催化剂选自对甲苯磺酸,樟脑磺酸,盐酸,醋酸,硫酸,或三氟乙酸等;所述路易斯酸催化剂选自三氟化硼乙醚,TMSCl,TMSOTf,三氯化铝等。
所述缩合反应在溶剂中进行,所述溶剂选自乙醚、TMBE、异丙醚、THF、2-甲基THF、二氯甲烷、甲苯和正己烷中的一种或多种溶剂的混合物。
所述缩合反应的温度在-10摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
步骤(b)中,
所述缩合反应在醇类亲核试剂或硫醇类亲核试剂存在下进行;所述醇类亲核试剂选自甲醇,或乙醇等;所述硫醇类亲核试剂选自甲硫醇,或乙硫醇等。
所述缩合反应在质子酸催化剂或路易斯酸催化剂存在下进行,所述质子酸催化剂选自对甲苯磺酸,樟脑磺酸,盐酸,醋酸,硫酸,或三氟乙酸等;所述路易斯酸催化剂选自三氟化硼乙醚,TMSCl,TMSOTf,三氯化铝等。
所述缩合反应在溶剂中进行,所述溶剂选自乙醚、TMBE、异丙醚、THF、2-甲基THF、二氯甲烷、甲苯和正己烷中的一种或多种溶剂的混合物。
所述缩合反应的温度在-10摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
步骤(c)中,
所述烯烃化反应为以Ph3P=CH2为亚甲基供体的Wittig反应,或使用Petasis试剂的,或使用Tebbe试剂的烯烃化反应。
所述缩合反应的温度在-78摄氏度到+80摄氏度之间,反应时间为1小时至24小时。
化合物23a和化合物23b还可以进一步发生反应:
(a)化合物23a发生氧化反应,生成化合物24a;或
(b)化合物23b发生氧化反应,生成化合物24b;或
(c)化合物23a与酰化剂发生酰化反应,生成化合物26a;或
(d)化合物23b与酰化剂发生酰化反应,生成化合物26b。
其中,
步骤(a)或(b)中,
所述氧化反应为基于二甲基亚砜的氧化反应、Dess-Martin氧化反应、PCC氧化反应或TEMPO催化的氧化反应。
当所述氧化反应是基于二甲基亚砜的氧化反应时,所述氧化反应以DMSO和活化剂为氧化剂,在有机碱的存在下,于卤代烃溶剂中,在-78摄氏度至+50摄氏度范围中进行,反应时间为0.5小时至12小时。所述卤代烃溶剂选自二氯甲烷、1,2-二氯乙烷、以及氯仿;所述活化剂选自草酰氯、吡啶-三氧化硫配合物、N-氯代丁二酰亚胺、醋酐、三氟乙酸酐等;所述有机碱选自三乙胺、二异丙基乙胺、DBU等。
当所述氧化反应是Dess-Martin氧化反应时,所述氧化反应以Dess-Martin试剂为氧化剂,于卤代烃或醚类溶剂中,在-20摄氏度至+50摄氏度范围中进行,反应时间为0.5小时至12小时。所述卤代烃溶剂选自二氯甲烷、1,2-二氯乙烷、以及氯仿;所述醚类烃溶剂选自THF,乙醚、叔丁基甲基醚等。
当所述氧化反应是PCC氧化时,所述氧化反应以三氧化铬吡啶盐酸盐为氧化剂,于卤代烃溶剂中,在-78摄氏度至+50摄氏度范围中进行,反应时间为0.5小时至12小时。所述卤代烃溶剂选自二氯甲烷、1,2-二氯乙烷、以及氯仿。
当所述氧化反应是TEMPO催化的氧化反应时,所述氧化反应以次氯酸钙、次氯酸钠、或三氯异氰尿酸为氧化剂,以四甲基哌啶氮氧化物(TEMPO)为催化剂于卤代烃溶剂中,在-78摄氏度至+50摄氏度范围中进行,反应时间为0.5小时至12小时。所述卤代烃溶剂选自二氯甲烷、1,2-二氯乙烷、以及氯仿。
步骤(c)或(d)中,
所述酰化剂为甲磺酰氯;
所述酰化反应在缚酸剂存在下进行,所述缚酸剂选自三乙胺、DIPEA或DBU等;
所述酰化反应在溶剂中进行,所述溶剂选自二氯甲烷、三氯甲烷、乙腈、TBME、DMF和THF中的一种或多种溶剂的混合物;
所述酰化反应的温度在-100摄氏度到+100摄氏度之间,反应时间为12小时至48小时。
所述化合物24a、化合物24b还可以进一步发生反应:
(a)化合物24a与还原剂及胺基供体发生还原胺化反应,生成化合物25a;或
(b)化合物24b与还原剂及胺基供体发生还原胺化反应,生成化合物25b;或
(c)化合物24b与还原剂及R1ONH2或其盐发生还原胺化反应,生成化合物25c;或
(d)化合物24a单保护胺PG3NH2或双保护胺PG3NHPG3发生还原胺化反应,生成化合物28a1或28a2;或
(e)化合物24b单保护胺PG3NH2或双保护胺PG3NHPG3发生还原胺化反应,生成化合物28b1或28b2。
其中,R1为THP-、TBS-、甲基或氢;PG3选自叔丁氧羰基、苄氧羰基、邻苯二甲酰基或三氯乙酰基或邻硝基苯磺酰基。当PG3为邻苯二甲酰基时,则产物只会是28a1和28b1,不存在28a2和28b2;化合物28a1的结构为化合物28b1的结构为
其中,
步骤(a)中,
所述还原剂选自氰基硼氢化钠或三乙酰氧基硼氢化钠;
所述胺基供体为PG3NH2或PG3NH,例如BocNH2、PhthNH、CbzNH2、Boc2NH、NsNH2等;
所述还原胺化反应在酸催化剂存在下进行,所述酸催化剂选自三氟乙酸、盐酸、甲酸或乙酸;
所述还原胺化反应过程中控制反应液的pH在0到10之间;
所述还原胺化反应在溶剂中进行,所述溶剂选自二氯甲烷、三氯甲烷、乙腈、TBME、甲醇、乙醇、水和THF中的一种或多种溶剂的混合物。
所述还原胺化反应的温度在-20摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
步骤(b)中,
所述还原剂选自氰基硼氢化钠或三乙酰氧基硼氢化钠;
所述胺基供体为PG3NH2或PG3NH,例如BocNH2、PhthNH、CbzNH2、Boc2NH、NsNH2等;
所述还原胺化反应在酸催化剂存在下进行,所述酸催化剂选自三氟乙酸、盐酸、甲酸或乙酸;
所述还原胺化反应过程中控制反应液的pH在0到10之间;
所述还原胺化反应在溶剂中进行,所述溶剂选自二氯甲烷、三氯甲烷、乙腈、TBME、甲醇、乙醇、水和THF中的一种或多种溶剂的混合物。
所述还原胺化反应的温度在-20摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
步骤(c)中,
所述还原剂选自氰基硼氢化钠或三乙酰氧基硼氢化钠;
所述还原胺化反应在酸催化剂存在下进行,所述酸催化剂选自三氟乙酸、盐酸、甲酸或乙酸;
所述还原胺化反应过程中控制反应液的pH在0到10之间;
所述还原胺化反应在溶剂中进行,所述溶剂选自二氯甲烷、三氯甲烷、乙腈、TBME、甲醇、乙醇、水和THF中的一种或多种溶剂的混合物。
所述还原胺化反应的温度在-20摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
步骤(d)中,
所述胺基供体为PG3NH2或PG3NH,例如BocNH2、PhthNH、CbzNH2、Boc2NH、NsNH2等;
所述还原胺化反应在还原剂存在下进行,所述还原剂选自氰基硼氢化钠或三乙酰氧基硼氢化钠;
所述还原胺化反应在酸催化剂存在下进行,所述酸催化剂选自三氟乙酸、盐酸、甲酸、或乙酸;
所述还原胺化反应中控制反应液的pH在0到10之间;
所述还原胺化反应在溶剂中进行,所述溶剂选自括二氯甲烷、三氯甲烷、乙腈、TBME、甲醇、乙醇、水和THF中的一种或多种溶剂的混合物。
所述还原胺化反应的温度在-20摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
步骤(e)中,
所述还原胺化反应在胺基供体存在下进行,所述胺基供体为PG3NH2或PG3NH,例如BocNH2、PhthNH、CbzNH2、Boc2NH、NsNH2等;
所述还原胺化反应在还原剂存在下进行,所述还原剂选自氰基硼氢化钠或三乙酰氧基硼氢化钠;
所述还原胺化反应在酸催化剂存在下进行,所述酸催化剂选自三氟乙酸、盐酸、甲酸、或乙酸;
所述还原胺化反应中控制反应液的pH在0到10之间;
所述还原胺化反应在溶剂中进行,所述溶剂选自二氯甲烷、三氯甲烷、乙腈、TBME、甲醇、乙醇、水和THF中的一种或多种溶剂的混合物。
所述还原胺化反应的温度在-20摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
其中,化合物25c可以发生反应生成化合物25b:
化合物25c发生还原反应,生成化合物25b。
所述还原反应在氢化物存在下进行,所述氢化物选自锂铝氢、硼氢化锂、三仲丁基硼氢化锂(L-selectride)、三异丁基硼氢化钾(K-selectride)、硼氢化钠、氰基硼氢化钠或三乙酰氧基硼氢化钠等;
所述还原反应在溶剂中进行,所述溶剂选自水、二氯甲烷,三氯甲烷,乙腈,TBME,DMF和THF中的一种或多种溶剂的混合物;
所述还原反应的温度在-100摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
化合物26a和化合物26b可以进一步发生反应:
(a)化合物26a与叠氮化试剂发生取代反应,生成化合物27a;或
(b)化合物26b与叠氮化试剂发生取代反应,生成化合物27b。
其中,
步骤(a)中,
所述叠氮化试剂为NaN3;
所述取代反应在溶剂中进行,所述溶剂选自二氯甲烷、三氯甲烷、乙腈、TBME、DMF和THF中的一种或多种溶剂的混合物;
所述还原反应的温度在-100摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
化合物27a还可通过化合物23a与叠氮磷酸二苯酯的反应而获得。
步骤(b)中,
所述叠氮化试剂为NaN3;
所述取代反应在溶剂中进行,所述溶剂选自二氯甲烷、三氯甲烷、乙腈、TBME、DMF和THF中的一种或多种溶剂的混合物;
所述取代反应的温度在-100摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
化合物27b还可通过化合物23b与叠氮磷酸二苯酯的反应而获得。
化合物27a和化合物25a可以进一步发生反应:
(a)化合物27a发生还原反应,生成化合物25a;或
(b)化合物27b发生还原反应,生成化合物25b。
其中,
步骤(a)中,
所述还原反应在膦试剂或氢化物存在下进行,所述膦试剂选自三苯基膦、三甲基磷或三正丁基膦;所述氢化物选自硼氢化钠、氰基硼氢化钠或三乙酰氧基硼氢化钠等;
所述还原反应在溶剂中进行,所述溶剂选自水、二氯甲烷、三氯甲烷、乙腈、TBME、DMF和THF中的一种或多种溶剂的混合物;
所述还原反应的温度在-100摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
步骤(b)中,
所述还原反应在膦试剂或氢化物存在下进行,所述膦试剂选自三苯基膦、三甲基磷或三正丁基膦;所述氢化物选自硼氢化钠、氰基硼氢化钠或三乙酰氧基硼氢化钠等;
所述还原反应在溶剂中进行,所述溶剂选自水、二氯甲烷、三氯甲烷、乙腈、TBME、DMF和THF中的一种或多种溶剂的混合物;
所述还原反应的温度在-100摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
化合物25a和化合物25b可以发生如下反应:
(a)化合物25a与酰化剂PG3Cl或PG3OPG3发生酰化反应,生成化合物28a1或28a2。
(b)化合物25b与酰化剂PG3Cl或PG3OPG3发生酰化反应,生成化合物28b1或28b2。
其中,
步骤(a)中,
所述酰化反应在缚酸剂存在下进行,所述缚酸剂选自吡啶、三乙胺、DIPEA、DBU或无机碱,所述无机碱选自碳酸钠、碳酸钾、碳酸氢钠等;
所述酰化反应在溶剂中进行,所述溶剂选自吡啶、二氯甲烷、三氯甲烷、乙腈、TBME、甲醇、乙醇、水和THF中的一种或多种溶剂的混合物。
所述酰化反应的温度在-20摄氏度到+100摄氏度之间,反应时间为1小时至24小时。步骤(b)中,
所述酰化反应在缚酸剂存在下进行,所述缚酸剂选自吡啶、三乙胺、DIPEA、DBU或无机碱,所述无机碱选自碳酸钠、碳酸钾、碳酸氢钠等;
所述酰化反应在溶剂中进行,所述溶剂选自吡啶、二氯甲烷、三氯甲烷、乙腈、TBME、甲醇、乙醇、水和THF中的一种或多种溶剂的混合物。
所述酰化反应的温度在-20摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
化合物28a1、28a2和化合物28b1、28b2可以进一步发生反应:
(a)化合物28a1或28a2发生氧化反应,分别生成化合物29a或29b;或
(b)化合物28b1或28b2发生氧化反应,分别生成化合物29a或29b。
其中,X、Y、A、B、n和PG3的定义同前所述。
其中,
步骤(a)中,
所述氧化反应在氧化试剂、含汞化合物或含镉化合物存在下进行;
所述氧化试剂选自NCS(N-氯代丁二酰亚胺)、NBS(N-溴代丁二酰亚胺)、NIS(N-碘代丁二酰亚胺)、过硫酸钾、过氧化氢或次氯酸钠等;
所述含汞化合物选自氯化汞、二氯化汞或氧化汞等;
所述含镉化合物选自氯化镉、碳酸镉或氧化镉等;
所述氧化反应优选在质子酸或路易斯酸存在下进行;所述质子酸选自对甲苯磺酸、樟脑磺酸、盐酸、醋酸、硫酸或三氟乙酸等;所述路易斯酸选自三氟化硼乙醚、TMSCl、TMSOTf或三氯化铝等;
所述氧化反应在溶剂中进行,所述溶剂选自二氯甲烷、三氯甲烷、乙腈、丙酮、水、TBME、DMF和THF中的一种或多种溶剂的混合物;
所述氧化反应的温度在-10摄氏度到+100摄氏度之间,反应时间为1小时至12小时。
步骤(b)中,
所述氧化反应在氧化试剂、含汞化合物或含镉化合物存在下进行;
所述氧化试剂选自NCS(N-氯代丁二酰亚胺)、NBS(N-溴代丁二酰亚胺)、NIS(N-碘代丁二酰亚胺)、过硫酸钾、过氧化氢或次氯酸钠等;
所述含汞化合物选自氯化汞、二氯化汞或氧化汞等;
所述含镉化合物选自氯化镉、碳酸镉或氧化镉等;
所述氧化反应在质子酸或路易斯酸存在下进行;所述质子酸选自对甲苯磺酸、樟脑磺酸、盐酸、醋酸、硫酸或三氟乙酸等;所述路易斯酸选自三氟化硼乙醚、TMSCl、TMSOTf或三氯化铝等;
所述氧化反应在溶剂中进行,所述溶剂选自二氯甲烷、三氯甲烷、乙腈、丙酮、水、TBME、DMF和THF中的一种或多种溶剂的混合物;
所述氧化反应的温度在-100摄氏度到+100摄氏度之间,反应时间为1小时至12小时。
化合物29a或29b可以进一步发生反应:
化合物29a或29b发生还原胺化反应,分别生成化合物30a或30b。
其中,PG3的定义同前所述。
其中,
所述胺基供体选自化合物10、化合物10a或化合物10b等;化合物10、化合物10a和化合物10b的结构式如下:
所述还原胺化反应在还原剂存在下进行,所述还原剂选自氰基硼氢化钠或三乙酰氧基硼氢化钠;
所述还原胺化反应在酸催化剂存在下进行,所述酸催化剂选自三氟乙酸、盐酸、甲酸或乙酸;
所述还原胺化反应中控制反应液的pH在0到10之间;
所述还原胺化反应在溶剂中进行,所述溶剂选自二氯甲烷、三氯甲烷、乙腈、TBME、甲醇、乙醇、DMF、DMAc、甲酰胺、水和THF中的一种或多种溶剂的混合物。
所述还原胺化反应的温度在-20摄氏度到+100摄氏度之间,反应时间为6小时至48小时。
化合物30a或30b可以进一步发生反应:
化合物30a或30b发生氢化反应、或者亲核脱保护反应、或者碱性脱保护反应,或者还原脱保护反应,生成化合物1。其中,Pg’的定义同前所述。
当PG3为苄氧羰基时,可以经过氢化反应生成化合物1;所述氢化反应在如下条件下进行:
所述氢化反应优选在质子酸或路易斯酸存在下进行,所述质子酸选自对甲苯磺酸、樟脑磺酸、盐酸、醋酸、硫酸或三氟乙酸等;所述路易斯酸选自三氟化硼乙醚、TMSCl、TMSOTf或三氯化铝等;
所述氢化反应在含有Pd、Pt或者Ni的催化剂存在下进行,包括但不仅限于钯碳、钯黑、氧化钯、醋酸钯、铂炭、氧化铂、雷尼镍等;
所述氢化反应在氢供体存在下进行,所述氢供体包括氢气、转移氢化氢供体或采用活泼金属与质子溶剂的组合作为氢供体;所述转移氢化氢供体选自甲酸铵,环己烯,四氢化萘,环己二烯,甲基环己二烯,或2,6-二甲基-1,4-二氢-3,5-吡啶二羧酸二乙酯(Hantzsch ester)等;所述采用活泼金属与质子溶剂的组合作为氢供体,其中活泼金属选自锌、锌汞齐、钠汞齐、或镁,质子溶剂选自甲醇、乙醇、异丙醇或水。
所述氢化反应在溶剂中进行,所述溶剂选自甲醇、乙醇、异丙醇、二氯甲烷、三氯甲烷、乙腈、丙酮、水、TBME、DMF和THF中的一种或多种溶剂的混合物;
所述氢化反应的温度在-20摄氏度到+100摄氏度之间,反应时间为6小时至48小时。
当PG3为邻硝基苯磺酰基时,可以经过亲核脱保护反应生成化合物1;所述亲核脱保护反应在含硫亲核试剂存在下进行,所述含硫亲核试剂选自乙硫醇、1-癸硫醇、苯硫酚、对甲基苯硫酚、巯基乙醇或巯基乙酸。
所述亲核脱保护反应的温度在-20摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
当PG3为邻苯二甲酰基时,可以经过碱性脱保护反应生成化合物1;所述碱性脱保护反应在含氮有机碱存在下进行,所述含氮有机碱选自肼、水合肼、甲基肼、不对称二甲基肼、羟胺或O-甲基羟胺。
所述碱性脱保护反应的温度在-20摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
当PG3为三氯乙酰基时,可以经过还原脱保护反应生成化合物1;所述还原脱保护反应在金属还原剂存在下进行,所述金属还原剂选自金属锌、钠汞齐或锌汞齐。
所述还原脱保护反应的温度在-20摄氏度到+100摄氏度之间,反应时间为1小时至24小时。
本发明的有益效果:
通过以上步骤,可实现多种新型四氢吡喃手性衍生物的合成,也包括化合物1的合成。
具体实施方式
实施例1
化合物14-1的制备
无水无氧条件下,将2,5-二氟溴苯(28.7g,0.149mol)溶于150mL无水乙醚中,冷却至-98℃,滴加n-BuLi(62mL,99mmol,1.6M in hexane),反应10min后,滴入中间体12-1(15g,0.05mol)的无水乙醚溶液,滴加完毕后,保持-98℃,反应1h,TLC检测反应完毕后,加饱和NH4Cl水溶液(100mL)淬灭反应,恢复至室温后,用TBME(100mL×4)萃取4次,合并有机层,用无水硫酸钠干燥,真空蒸干有机溶剂,甲苯(50mL×2)共沸除水两次,通过快速制备色谱分离得到无色油状物14-1(20g,0.048mmol),产率:97%。1H-NMR(400MHz,CDCl3)δ7.43–7.33(m,1H),7.03–6.93(m,2H),4.32–4.23(m,2H),4.21(d,J=5.8Hz,1H),4.15(t,J=5.7Hz,1H),4.08(d,J=12.5Hz,1H),4.02(s,1H),1.53(s,3H),1.36(s,3H),0.74(s,9H),0.06(s,3H),-0.30(s,3H).
实施例2
化合物15-1的制备
在氮气保护下,将中间体14-1(20g,0.048mol)溶于200mL干燥的CH2Cl2中,冷却至-78℃,加入Et3SiH(8.4mL,0.053mol),搅拌5min后,滴加TMSOTf(10.2mL,0.053mol),反应1h,TLC检测反应完毕后,加饱和碳酸氢钠水溶液(100mL)淬灭反应,水层用CH2Cl2(100mL×3)萃取3次,合并有机层,无水硫酸钠干燥,浓缩,硅胶柱分离纯化(10:1,60-90℃petroleumether–EtOAc)得到白色晶状固体15-1(18.8g,0.047mol),产率:98%。M.p.72.1-76.6℃(60-90℃petroleum ether–EtOAc);Rf 0.52(10:1,60-90℃petroleum ether–EtOAc);[α]D-72.90(c 0.155CHCl3);HPLC tR 4.49min;1H-NMR(600MHz,CDCl3)δ7.17(ddd,J=8.4,5.0,3.0Hz,1H,ArH),6.99–6.90(m,2H,ArH),4.36(d,J=13.6Hz,1H,H-5),4.32(d,J=9.5Hz,1H,H-1),4.26(dd,J=5.6,2.0Hz,1H,H-4),4.10(t,J=6.2Hz,1H,H-3),3.88(dd,J=13.7,2.4Hz,1H,H-5’),3.68(dd,J=9.4,6.9Hz,1H,H-2),1.59(s,3H,OC(CH3 )2O),1.40(s,3H,OC(CH3 )2O),0.68(s,9H,C(CH 3)3),0.01(s,3H,SiCH 3),-0.40(s,3H,SiCH 3);13C-NMR(126MHz,CDCl3)δ160.16–158.02(m),157.75–155.64(m),128.71(dd,J C-C-F=16.2,7.5Hz),116.47(dd,J C-C-F=25.5,8.5Hz),115.92(dd,J C-C-F=24.2,8.7Hz),114.89(dd,JC-C-F=24.7,4.3Hz),109.55(OC(CH3)2O),80.35(C-3),75.84(C-2),74.68(C-1),74.16(C-4),67.49(C-5),28.40(OC(CH3)2O),26.57(OC(CH3)2O),25.62(C(CH3)3),17.91(C(CH3)3),-4.21(SiCH3),-5.71(SiCH3)。
实施例3
化合物16-1的制备
将中间体15-1(12g,29.96mmol,)溶于无水四氢呋喃(100mL)中,加入正丁基氟化铵(44.94mL,44.94mmol,1M in THF),室温搅拌过夜,反应完毕后,蒸干THF,加EA(200mL)稀释,用水(50mL×3)洗有机层三次,饱和食盐水(50mL)洗EA层,无水硫酸钠干燥,浓缩,得油状产物16-1。
实施例4
化合物17-1的制备
在氮气保护下,中间体16-1溶于无水CH2Cl2(150mL),冷却至0℃,加入三乙胺(31.3mL,0.225mol),然后缓慢滴加甲磺酰氯(5.8mL,74.9mmol),滴加完毕后,室温反应40min,加MeOH(5mL)淬灭反应,搅拌10min,用饱和碳酸氢钠溶液(50mL×3)洗有机层三次,最后用饱和氯化钠溶液(50mL)洗有机层,无水硫酸钠干燥后,浓缩,硅胶柱分离纯化(4:1,60-90℃petroleum ether–EtOAc),得到白色固体产物17(9.28g,25.46mmol),产率:85%。M.p.162.0-164.4℃(60-90℃petroleum ether–EtOAc);Rf 0.77(2:1,60-90℃petroleumether–EtOAc);[α]D-110.67(c 0.15CHCl3);HPLC tR 3.00min;1H-NMR(600MHz,CDCl3)δ7.24(ddd,J=8.4,5.2,3.0Hz,1H,ArH),7.09–6.95(m,2H,ArH),4.64(dd,J=10.0,6.8Hz,1H,H-2),4.51(d,J=9.9Hz,1H,H-1),4.44(d,J=13.8Hz,1H,H-5),4.37(d,J=5.4Hz,1H,H-3),4.36(s,1H,H-4),3.93(dd,J=13.8,2.0Hz,1H,H-5’),2.95(s,3H,OSO2CH3 ),1.64(s,3H,OC(CH3 )2O),1.42(s,3H,OC(CH3 )2O);13C-NMR(151MHz,CDCl3)δ160.12–157.98(m),156.41(dd,J C-F=243.4,2.2Hz),125.61(dd,J C-C-F=15.8,7.6Hz),117.11(dd,J C-C-F=24.2,8.7Hz),116.57(dd,J C-C-F=25.1,8.4Hz),114.97(dd,J C-C-F=25.2,3.7Hz),110.77(OC(CH3)2O),83.01(C-2),77.10(C-3),74.45(C-4),72.17(C-1),67.24(C-5),39.02(OSO2 CH3),28.02(OC(CH3)2O),26.43(OC(CH3)2O).
实施例5
化合物18-1的制备
将中间体17-1(9.0g,24.7mmol)溶于丙酮(20mL)中,加到1N H2SO4水溶液中,加热到100℃,回流30min至反应液澄清,冰浴冷却至0℃,用乙酸乙酯(100mL×3)萃取水层三次,合并有机层,用饱和碳酸氢钠(100mL×2)洗2次,饱和食盐水(100mL)洗,无水硫酸钠干燥,浓缩,硅胶柱分离纯化(15:1,DCM–MeOH),得到白色固体产物18-1(7.77g,23.96mmol),产率:97%。1H-NMR(400MHz,CDCl3)δ7.36–7.28(m,1H),7.05(tdd,J=8.3,7.5,4.3,2.0Hz,2H),4.77(t,J=9.4Hz,1H),4.59(d,J=9.3Hz,1H),4.22(dd,J=12.9,1.9Hz,1H),4.17–4.12(m,1H),3.94(ddd,J=8.9,5.3,3.6Hz,1H),3.73(d,J=12.8Hz,1H),3.51(d,J=5.5Hz,1H),2.88(d,J=2.8Hz,1H),2.74(s,3H).
实施例6
化合物19-1的制备
将中间体18-1(7.77g,23.96mmol)溶于100mL无水甲醇(100mL)中,分批加入甲醇钠(5.18g,95.84mmol),加热至50℃,搅拌反应30min,恢复至室温后,加饱和氯化铵溶液(50mL)淬灭反应,用二氯甲烷(50mL×3)萃取三次,合并有机层,饱和碳酸氢钠(100mL)洗一次,饱和氯化钠溶液(100mL)洗一次,无水硫酸钠干燥,浓缩,硅胶柱分离纯化(2:1,60-90℃petroleum ether–EtOAc),得到化合物19-1(5.2g,22.76mmol),产率95%。M.p.80.6-82.7℃(60-90℃petroleum ether–EtOAc);Rf 0.52(2:1,60-90℃petroleum ether–EtOAc);[α]D-120.67(c 0.15CHCl3);HPLC tR 2.23min;1H-NMR(500MHz,CDCl3)δ7.30(ddd,J=8.8,5.5,3.1Hz,1H,ArH),7.06–6.96(m,2H,ArH),5.02(s,1H,H-1),3.96(d,J=12.6Hz,2H,H-4,H-5),3.69–3.65(m,1H,H-3),3.59(dd,J=12.6,3.0Hz,1H,H-5’),3.51(d,J=3.9Hz,1H,H-2),2.76(d,J=10.9Hz,1H,4-OH);13C-NMR(126MHz,CDCl3)δ159.10(dd,J C-F=242.7,1.9Hz),155.54(dd,J C-F=241.4,2.3Hz),127.42(dd,J C-C-F=16.0,7.9Hz),116.34–116.09(m),116.22(dd,J C-C-F=24.4,19.1Hz),115.46(dd,J C-C-F=25.7,4.3Hz),71.49(C-5),68.90(C-1),61.50(C-4),54.20(C-2),53.33(C-3);HRMS(ESI+)calcd.ForC11H10O3F2Na+251.0490,found 251.0483.
实施例7
化合物20b-1的制备
将中间化合物19-1(5.0g,21.9mmol)溶于无水二氯甲烷(50mL)中,分批加入Dess-Martin氧化剂(18.6g,43.8mmol),室温搅拌反应3h,加饱和碳酸氢钠和硫代硫酸钠水溶液淬灭反应至没有气泡产生,分离有机层,用二氯甲烷(20mL×3)萃取水层三次,合并有机层,用饱和食盐水(50mL)洗有机层,无水硫酸钠干燥,浓缩,用硅胶柱分离纯化(8:1,60-90℃petroleum ether–EtOAc),得到灰白色固体20b-1(4.56g,20.15mmol),产率:92%。M.p.68.7-71.3℃(Dichloromethane);Rf 0.39(4:1,60-90℃petroleum ether–EtOAc);[α]D-274.29(c 0.14CHCl3);HPLC tR 2.09min;1H-NMR(500MHz,CDCl3)δ7.37(ddd,J=8.6,5.5,3.1Hz,1H,ArH),7.11–7.01(m,2H,ArH),5.23(s,1H,H-1),4.50(d,J=18.5Hz,1H,H-5),4.12(d,J=18.5Hz,1H,H-5’),3.77(d,J=3.9Hz,1H,H-2),3.53(d,J=3.9Hz,1H,H-3);13C-NMR(126MHz,Chloroform-d)δ200.80(C=O),159.17(dd,J C-F=243.5,1.9Hz),155.51(dd,JC-F=241.8,2.3Hz),126.52(dd,J C-C-F=15.8,8.0Hz),116.78(dd,J C-C-F=22.1,6.4Hz),116.53(dd,J C-C-F=22.0,6.3Hz),115.18(dd,J C-C-F=25.8,3.9Hz),72.75(C-5),67.30(C-1),55.49(C-2),54.42(C-3);HRMS(ESI-)calcd.For C11H7O3F2 -225.0363,found225.0364.
实施例8
化合物22-1的制备
将中间体20b-1(4.5g,19.9mmol)溶于丙酮(45mL)中,避光条件下,依次加入NaI(11.04g,73.6mmol),冰醋酸(22.74mL,39.77mmol),NaOAc·3H2O(0.81g,5.97mmol),室温搅拌反应4h,加入饱和碳酸氢钠和硫代硫酸钠溶液至红棕色颜色褪去,淬灭反应,二氯甲烷(20mL×3)萃取三次,合并有机层,饱和食盐水(30mL)洗,无水硫酸钠干燥,浓缩,硅胶柱分离纯化(4:1,60-90℃petroleum ether–EtOAc),得到无色油状产物22(4.04g,17.7mmol),产率:89%。Rf 0.43(2:1,60-90℃petroleum ether–EtOAc);[α]D-53(c 0.1CHCl3);HPLCtR 2.15min;1H-NMR(500MHz,CDCl3)δ7.29(ddd,J=8.8,5.5,3.2Hz,1H,ArH),7.07–6.98(m,2H,ArH),5.12(s,1H,H-1),4.50(s,1H,H-2),4.38(dd,J=16.2,1.2Hz,1H,H-5),4.22(d,J=16.2Hz,1H,H-5’),3.47(s,2-OH),2.88–2.87(m,2H,H-3,H-3’);13C-NMR(126MHz,Chloroform-d)δ204.92(C=O),159.01(dd,J C-F=242.9,2.1Hz),155.07(dd,J C-F=241.1,2.5Hz),126.92(dd,J C-C-F=15.5,7.9Hz),116.38(dd,J C-C-F=24.2,8.5Hz),115.99(dd,JC-C-F=24.3,8.7Hz),115.20(dd,J C-C-F=25.9,4.5Hz),74.91(C-5),74.16(C-1),68.75(d,J C-O=2.0Hz,C-2),46.09(C-3);HRMS(ESI-)calcd.For C11H9O3F2 -227.0520,found 227.0519。
实施例9
化合物15-2的制备
从化合物12-1(3.0g,9.92mmol,1.0equiv.),13-2(2.39g,19.84mmol,2.0equiv.),n-BuLi(13.6mL,1.6M in hexanes,21.82mmol,2.2equiv.),TMSOTf(2.11mL,10.91mmol,1.1equiv.),以及Et3SiH(1.74mL,10.91mmol,1.1equiv.)出发,同实施例1和实施例2的操作,经粗产物14-2得到产物15-2(白色固体,2.62g,65%)。M.p.62.3-63.4℃(60-90℃petroleum ether–EtOAc);Rf 0.42(10:1,60-90℃petroleum ether–EtOAc);[α]D-19.35(c 0.155CHCl3);HPLC tR 4.51min;1H NMR(600MHz,CDCl3)δ4.32(s,1H,Dithiane-CH),4.31(d,J=12Hz,1H,H-5),4.15(dd,J=5.6,1.7Hz,1H,H-4),3.95(t,J=6.2Hz,1H,H-3),3.87(dd,J=9.3,6.8Hz,1H,H-2),3.72(dd,J=13.5,2.4Hz,1H,H-5’),3.32(dd,J=9.3,1.7Hz,1H,H-1),3.04(ddd,J=13.6,6.0,2.5Hz,1H,Dithiane-CH 2),3.02–2.94(m,1H,Dithiane-CH 2),2.86(ddd,J=13.4,10.5,2.5Hz,1H,Dithiane-CH 2),2.69(ddd,J=13.4,10.4,2.4Hz,1H,Dithiane-CH 2),2.07(ddt,J=12.7,6.3,3.6Hz,1H,Dithiane-CH 2),1.98(tdd,J=13.7,6.7,2.8Hz,1H,Dithiane-CH 2),1.53(s,3H,OC(CH3 )2O),1.35(s,3H,OC(CH3 )2O),0.90(s,9H,C(CH3 ) 3 ),0.18(s,3H,SiCH3 ),0.16(s,3H,SiCH3 );13C NMR(151MHz,CDCl3)δ109.46(OC(CH3)2O),83.90(C-1),80.18(C-3),73.97(C-4),71.41(C-2),67.30(C-5),46.89(Dithiane-CH),30.59(Dithiane-CH2),29.75(Dithiane-CH2),28.26(OC(CH3)2O),26.62(OC(CH3)2O),26.27(Dithiane-CH2),26.08(C(CH3)3),18.25(C(CH3)3),-4.00(SiCH3),-4.96(SiCH3);HRMS(ESI+)calcd.For C18H34O4NaS2Si+429.1560,found 429.1552.
实施例10
化合物17-2的制备
从化合物15-2(2.0g,4.91mmol,1.0equiv.),TBAF(1M in THF,7.37mL,7.37mmol,1.5equiv.),以及MsCl(0.76mL,9.83mmol,2.0equiv.)出发,同实施例3和实施例4的操作,经粗产物16-2得到化合物17-2(白色固体,1.4g,77%).M.p.156.0-158.1℃(60-90℃petroleum ether–EtOAc);Rf 0.64(2:1,60-90℃petroleum ether–EtOAc);[α]D-48.0(c0.175CHCl3);HPLC tR 2.70min;1H NMR(600MHz,CDCl3)δ4.93–4.87(m,1H,H-2),4.38(d,J=13.7Hz,1H,H-5),4.26–4.22(m,3H,H-4,H-3,Dithiane-CH),3.76(dd,J=13.7,1.9Hz,1H,H-5’),3.56(dd,J=9.7,1.8Hz,1H,H-1),3.22(s,3H,OSO2CH3 ),3.05(dddd,J=14.3,9.7,7.2,3.3Hz,2H,Dithiane-CH2 ),2.90(ddd,J=13.4,10.0,2.7Hz,1H,Dithiane-CH 2),2.77(ddd,J=13.6,10.0,2.6Hz,1H,Dithiane-CH 2),2.11–2.06(m,1H,Dithiane-CH 2),2.01–1.94(m,1H,Dithiane-CH 2),1.60(s,3H,OC(CH3 )2O),1.38(s,3H,OC(CH3 )2O);13C NMR(151MHz,CDCl3)δ110.77(OC(CH3)2O),81.66(C-1),79.49(C-2),77.11,74.04,66.78(C-5),45.82(Dithiane-CH),39.26(OSO2 CH3),30.28(Dithiane-CH2),29.66(Dithiane-CH2),27.89(OC(CH3)2O),26.48(OC(CH3)2O),25.98(Dithiane-CH2);HRMS(ESI+)calcd.ForC13H23O6S3 +371.0651,found 371.0646.
实施例11
化合物19-2的制备
从化合物17-2(1.4g,3.77mmol,1.0equiv.)出发,同实施例5和实施例6的操作,经粗产物18-2得到化合物19-2(白色固体,556mg,63%)。M.p.92.6-94.6℃(60-90℃petroleum ether–EtOAc);Rf 0.2(2:1,60-90℃petroleum ether–EtOAc);[α]D 13.13(c0.16CHCl3);HPLC tR 1.68min;1H NMR(500MHz,CDCl3)δ4.41(d,J=8.6Hz,1H,Dithiane-CH),3.98–3.93(m,1H,H-4),3.91(dd,J=8.6,1.2Hz,1H,H-1),3.77(dd,J=12.3,3.1Hz,1H,H-5),3.62(dd,J=4.1,1.3Hz,1H,H-2),3.60(t,J=4.1Hz,1H,H-3),3.45(dd,J=12.3,3.6Hz,1H,H-5’),2.95–2.87(m,4H,Dithiane-CH2 x 2),2.57(d,J=11.1Hz,1H,4-OH),2.17–2.10(m,1H,Dithiane-CH 2),2.00–1.92(m,1H,Dithiane-CH 2);13C NMR(126MHz,CDCl3)δ73.94(C-1),69.51(C-5),62.33(C-4),53.34,53.20,48.12(Dithiane-CH),29.50(Dithiane-CH2),29.25(Dithiane-CH2),25.86(Dithiane-CH2);HRMS(ESI+)calcd.ForC9H14O3NaS2 +257.0277,found257.0270.
实施例12
化合物20b-2的制备
将中间化合物19-2(240mg,1.02mmol)溶于无水二氯甲烷(5mL)中,分批加入Dess-Martin氧化剂(849mg,2mmol),室温搅拌反应3h,加饱和碳酸氢钠和硫代硫酸钠水溶液淬灭反应至没有气泡产生,分离有机层,用二氯甲烷萃取水层三次,合并有机层,用饱和食盐水洗有机层,无水硫酸钠干燥,浓缩,用硅胶柱分离纯化得到20b-1(无色油状物,160mg,产率:67%)。HRMS(ESI-)calcd.For C10H17O4S2+265.0563(M+MeOH+H+),found265.0560。
实施例13
化合物22-2的制备
将中间体20b-2(100mg,0.431mmol)溶于丙酮(2mL)中,避光条件下,依次加入NaI(239mg,1.59mmol),冰醋酸(17mg,0.86mmol),NaOAc·3H2O(18mg,0.129mmol),室温搅拌反应3h,加入饱和碳酸氢钠和硫代硫酸钠溶液至红棕色颜色褪去,淬灭反应,二氯甲烷萃取三次,合并有机层,饱和食盐水洗,无水硫酸钠干燥,浓缩,硅胶柱分离纯化得到22-2(无色油状产物,81mg,产率:80%)。HRMS(ESI-)calcd.For C9H15O3S2 +235.0457,found235.0451。
实施例14
化合物23a-1的制备
将中间体22-1(400mg,1.75mmol)溶于20mL无水DCM中,氮气保护下,加入乙硫醇(0.315mL,4.38mmol),再缓慢滴加三氟化硼乙醚络合物(0.221mL,1.75mmol),室温搅拌反应1h,加饱和碳酸氢钠水溶液(10mL)淬灭反应,分离有机层,水层用二氯甲烷(10mL×2)萃取,合并有机层,无水硫酸钠干燥,浓缩,硅胶柱分离纯化(10:1,60-90℃petroleum ether–EtOAc),得到无色油状产物23a-1(533mg,1.59mmol),产率:91%。1H-NMR(600MHz,Chloroform-d)δ7.25(dt,J=5.3,3.3Hz,1H),6.94(dqd,J=16.3,9.0,4.1Hz,2H),4.75(s,1H),4.38(d,J=12.1Hz,1H),4.18(dd,J=12.2,2.8Hz,1H),3.99(d,J=12.1Hz,1H),3.94(d,J=12.2Hz,1H),2.83–2.72(m,2H),2.67(q,J=7.5Hz,2H),2.54(dt,J=14.8,2.7Hz,1H),2.12(dd,J=14.8,3.7Hz,1H),1.32(t,J=7.5Hz,3H),1.25(t,J=7.5Hz,3H).
实施例15
化合物23b-1的制备
参照实施例14中23a-1的制备方法,由中间体22-1(2.0g,8.76mmol)和乙二硫醇(2.06g,21.9mmol)制备得到白色固体产物23b-1(2.43g,7.98mmol),产率:91%。M.p.121.0–126.0℃(60-90℃petroleum ether–EtOAc);Rf 0.19(10:1,60-90℃petroleumether–EtOAc);[α]D-97.93(c 0.145CHCl3);HPLC tR 3.07min;1H-NMR(500MHz,CDCl3)δ7.29(ddd,J=8.9,5.5,3.1Hz,1H,ArH),7.00–6.90(m,2H,ArH),4.75(s,1H,H-1),4.13(dd,J=11.9,2.7Hz,1H,H-5),4.08(d,J=8.2Hz,1H,H-4),3.83(d,J=11.9Hz,1H,H-5’),3.39–3.25(m,4H,Dithiolane-CH2 ),2.69(d,J=8.9Hz,1H,2-OH),2.63(dt,J=14.6,2.7Hz,1H,H-3),2.53(dd,J=14.6,3.4Hz,1H,H-3’);13C-NMR(126MHz,CDCl3)δ159.98–157.95(m),154.97(dd,J C-F=240.7,2.5Hz),127.88(dd,J C-C-F=15.7,8.0Hz),116.00(dd,J C-C-F=24.3,8.5Hz),115.64–115.46(m),115.45–115.26(m),78.39(C-5),76.22(C-1),67.44(d,JC-O=1.8Hz,C-2),61.53(C-4),44.28(C-3),39.06(Dithiolane-CH2),37.87(Dithiolane-CH2)。
实施例16
化合物24a-1的制备
将中间体23a-1(1.0g,2.99mmol)溶于无水二氯甲烷(10mL)中,分批加入戴斯-马丁试剂(2.78g,6.57mmol),室温反应30min,加碳酸氢钠和硫代硫酸钠的饱和水溶液淬灭反应,分离有机相,水相用二氯甲烷(20mL×2)洗两次,合并有机相,饱和氯化钠溶液(20mL)洗,无水硫酸钠干燥,浓缩,硅胶柱分离纯化(10:1,60-90℃petroleum ether–EtOAc),得到白色固体产物24a-1(0.75g,2.12mmol),产率:71%。HRMS(ESI-)calcd.For C15H19F2O2S2+333.0789,found 333.0780.
实施例17
化合物24b-1的制备
将中间体23b-1(2.0g,6.57mmol)溶于无水二氯甲烷(20mL)中,分批加入戴斯-马丁试剂(5.57g,13.14mmol),室温反应30min,加碳酸氢钠和硫代硫酸钠的饱和水溶液淬灭反应,分离有机相,水相用二氯甲烷(20mL×2)洗两次,合并有机相,饱和氯化钠溶液(40mL)洗,无水硫酸钠干燥,浓缩,硅胶柱分离纯化(10:1,60-90℃petroleum ether–EtOAc),得到白色固体产物24b-1(1.79g,5.92mmol),产率:90%。M.p.95.6–98.5℃(Dichloromethane-MeOH);Rf 0.23(10:1,60-90℃petroleum ether–EtOAc);[α]D-101(c 0.1CHCl3);HPLC tR3.27min;1H-NMR(500MHz,CDCl3)δ7.12(ddd,J=8.4,5.3,2.9Hz,1H,ArH),7.07–6.98(m,2H,ArH),5.12(s,1H,H-1),4.24(dd,J=11.8,2.4Hz,1H,H-5),4.19(d,J=11.8Hz,1H,H-5’),3.49–3.33(m,4H,Dithiolane-CH2 ),3.24(dd,J=15.7,2.4Hz,1H,H-3),3.18(d,J=15.7Hz,1H,H-3’);13C-NMR(126MHz,CDCl3)δ199.45(2-C=O),158.83(dd,J C-F=242.5,1.9Hz),156.52(dd,J C-F=243.0,2.2Hz),124.39(dd,J C-C-F=16.5,8.3Hz),116.73(dd,JC-C-F=24.2,8.7Hz),116.39(dd,J C-C-F=24.6,8.5Hz),115.51(dd,J C-C-F=25.5,4.1Hz),79.13(C-1),76.76(C-5),66.56(C-4),54.90(C-3),40.33(Dithiolane-CH2),39.33(Dithiolane-CH2).
实施例18
化合物25b-1的制备
将中间体24b-1(1.0g,3.3mmol)溶于无水甲醇(10mL)中,加入醋酸铵(306mg,3.97mmol),室温搅拌5分钟后,分批缓慢加入氰基硼氢化钠(313mg,4.96mmol),室温搅拌反应过夜,加饱和碳酸氢钠水溶液(10mL)淬灭反应,用二氯甲烷(10mL×3)萃取3次,合并有机层,饱和食盐水(20mL)洗,无水硫酸钠干燥,浓缩,得25b-1粗品。
实施例19
化合物25c-1的制备
将中间体24b-1(1.0g,3.3mmol)溶于无水甲醇(10mL)中,加入盐酸羟胺(274mg,3.97mmol),室温搅拌5分钟后,分批缓慢加入氰基硼氢化钠(313mg,4.96mmol),室温搅拌反应过夜,加饱和碳酸氢钠水溶液(10mL)淬灭反应,用二氯甲烷(10mL×3)萃取3次,合并有机层,饱和食盐水(20mL)洗,无水硫酸钠干燥,浓缩,得25c-1粗品。
实施例20
化合物25b-1的制备
在无水无氧条件下,将中间体25c-1(100mg,0.313mmol)溶于2mL无水THF中,冷却至-78℃,缓慢滴加LAH(2.63mL,2.63mmol,1M in THF),滴加完毕后,自然升温至20℃,缓慢加水淬灭反应,用二氯甲烷(10mL×3)萃取三次,合并有机层,饱和食盐水(10mL)洗一次,无水硫酸钠干燥,浓缩,硅胶柱分离纯化得到中间体25b-1(62mg,0.203mmol),产率:65%。
实施例21
化合物28b1-1的制备
将所得25b-1粗品溶于无水二氯甲烷(10mL)中,加入三乙胺(2.77mL,19.8mmol),再加入CbzCl(1.12g,6.6mmol),室温反应4h,反应液用水(20mL×2)洗两次,饱和食盐水(20mL)洗,无水硫酸钠干燥,硅胶柱分离纯化(10:1,60-90℃ petroleum ether–EtOAc),得白色固体产物28b1-1。HRMS(ESI+)calcd.For C21H22F2NO3S2+438.1004,found 438.1000.
实施例22
化合物28b1-2的制备
将所得25b-1粗品溶于无水二氯甲烷(10mL)中,加入三乙胺(2.77mL,19.8mmol),再加入二碳酸二叔丁酯(1.44g,6.6mmol),室温反应4h,反应液用水(20mL×2)洗两次,饱和食盐水(20mL)洗,无水硫酸钠干燥,硅胶柱分离纯化(10:1,60-90℃petroleum ether–EtOAc),得白色固体产物28b1-2。M.p.156.6–159.0℃(Dichloromethane);Rf 0.2(10:1,60-90℃petroleum ether–EtOAc);[α]D-7.88(c 0.165CHCl3);HPLC tR 3.6min;1H-NMR(600MHz,CDCl3)δ7.28(s,1H,ArH),6.95(s,2H,ArH),4.45(d,J=9.0Hz,1H,NHBoc),4.42(d,J=9.9Hz,1H,H-1),4.00(dd,J=12.0Hz,1.8Hz,1H,H-5),3.86(d,J=9.0Hz,1H,H-2),3.74(d,J=11.6Hz,1H,H-5’),3.34(ddd,J=22.8,12.0,5.8Hz,4H,Dithiolane-CH2 ),2.63(d,J=12.9Hz,1H,H-3),2.19–2.01(m,1H,H-3’),1.27(s,9H,C(CH3 ) 3 );13C-NMR(151MHz,CDCl3)δ159.10(d,J C-F=243.0Hz),156.29(d,J C-F=240.6Hz),154.55(C=O),128.00(dd,J C-C-F=15.5,7.9Hz),116.40–116.13(m),116.13–115.81(m),115.34–115.07(m),79.75(C(CH3)3),77.84(C-5),76.01(C-1),64.88(C-4),52.80(C-2),46.52(C-3),38.96(Dithiolane-CH2),38.78(Dithiolane-CH2),28.24(C(CH3)3);HRMS(ESI+)calcd.ForC18H23O3NF2NaS2 +426.0980,found 426.0968.
实施例23
化合物29a-1的制备
将化合物28b1-1(427mg,1.06mmol)溶于乙腈和水(10mL:2mL)中,加入二(三氟乙酸)碘苯(683mg,1.59mmol),室温搅拌反应1h,加入饱和碳酸氢钠和硫代硫酸钠的水溶液淬灭反应,用二氯甲烷(15mL×3)萃取水层3次,合并有机层,饱和氯化钠溶液(20mL)洗有机层,无水硫酸钠干燥,浓缩,硅胶柱分离纯化(4:1,60-90℃petroleum ether–EtOAc),得白色固体产物29-1(274mg,0.837mmol),产率:79%。1H-NMR(400MHz,CDCl3)δ7.26–7.17(m,1H),7.06–6.98(m,2H),4.84(d,J=7.7Hz,1H),4.62(s,1H),4.30(d,J=16.3Hz,1H),4.12(d,J=16.3Hz,1H),4.09–3.99(m,1H),3.05(dd,J=16.0,6.2Hz,1H),2.82–2.64(m,1H),1.30(s,9H)。
实施例24
化合物29a-2的制备
将化合物28b1-1(437mg,1mmol)溶于乙腈和水(10mL:2mL)中,加入二(三氟乙酸)碘苯(683mg,1.59mmol),室温搅拌反应1h,加入饱和碳酸氢钠和硫代硫酸钠的水溶液淬灭反应,用二氯甲烷(15mL×3)萃取水层3次,合并有机层,饱和氯化钠溶液(20mL)洗有机层,无水硫酸钠干燥,浓缩,硅胶柱纯化得白色固体产物29-2(252mg,0.70mmol),产率:70%。HRMS(ESI+)calcd.For C19H17F2NO4+362.1198,found 362.1185。
实施例25
化合物30-1的制备
取三氟乙酸(2.6mL,35.0mmol)冷却至0℃,加入杂环化合物(500mg,1.74mmol),0~2℃反应1h。15℃以下缓慢加入N,N-二甲基乙酰胺(7.1mL,76.3mmol),三乙胺(2.4mL,17.3mmol),将反应液冷却至0℃,加入化合物29-1(660mg,1.83mmol),以及三乙酰氧基硼氢化钠(516.3mg,2.43mmol),0~2℃反应5h,加水(60mL),用乙酸乙酯萃取3次(30mL x3),合并有机相,无水硫酸钠干燥,减压蒸干溶剂,得到粗品30-1。HRMS(ESI+)calcd.ForC25H27F2N4O5S+533.1665,found 533.1559。
实施例26
化合物30-1的脱保护
取化合物30-1,溶于甲醇(10mL)中,加入Pd/C(10%,10mg),常压氢化2h,过滤并蒸干滤液,将残余物硅胶柱纯化得白色固体产物1。分析数据与文献(J.Med.Chem.2014,57,3205-3212)一致。
Claims (7)
4.权利要求1-3中任一项所示的式22所示化合物的制备方法,其包括如下步骤:化合物20b与还原剂发生2,3-环氧开环反应,生成式22所示的化合物;
其中,
R的定义同相对应的权利要求;
所述还原剂选自卤化物还原剂或氢化物还原剂;
所述氢化物还原剂选自氰基硼氢化钠或三乙酰氧基硼氢化钠;所述卤化物还原剂选自碘化钠、碘化钾、碘化锂或四丁基碘化铵,
其中,所述化合物20b由如下步骤制备:
(a)内酯12与金属盐13发生亲核加成反应,生成化合物14;
(b)化合物14与含有氢化硅结构的还原剂发生立体选择性还原反应,生成化合物15;
(c)化合物15发生2-O脱保护反应,生成化合物16;
(d)化合物16与酰化剂发生酰化反应,生成化合物17;
(e)化合物17发生3,4-O脱保护反应,脱除PG2保护基,生成化合物18;
(f)化合物18发生环氧化反应,生成化合物19;
(g)化合物19发生氧化反应,生成化合物20b;
其中,
R的定义同相对应的权利要求;
M为Mg或Li;
PG1选自三甲基硅基、三乙基硅基、叔丁基二甲基硅基、叔丁基二苯基硅基、对甲氧基苄基或苄基;
PG2选自苄叉基、对甲基苄叉基或丙叉基;
LG选自对甲基苯磺酰基、甲磺酰基、苯磺酰基、咪唑磺酰基或三氟甲磺酰基。
5.根据权利要求4所述的制备方法,其特征在于:所述还原剂为卤化物还原剂,所述2,3-环氧开环反应在反应促进剂存在下进行,所述反应促进剂选自醋酸、甲酸、丙酸、三氟乙酸、醋酸钠、甲酸钠、丙酸钠、或三氟乙酸钠。
6.根据权利要求4或5所述的制备方法,其特征在于:所述2,3-环氧开环反应在溶剂中进行,所述溶剂选自丙酮、甲醇、乙醇、二氯甲烷、三氯甲烷、乙腈、TBME、DMF、水和THF中的一种或多种溶剂的混合物。
7.权利要求3所述的式22所示化合物在用于制备化合物1中的用途,包括如下步骤:
(1a)式22所示化合物与X-H和Y-H发生缩合反应,生成化合物23a;或
其中,
X、Y各自独立地选自乙硫基、甲硫基、乙氧基或甲氧基;
A、B各自独立地为硫或氧;
n为1、2或3;
(2a)化合物23a发生氧化反应,生成化合物24a;或
(2b)化合物23b发生氧化反应,生成化合物24b;或
(2c)化合物23a与酰化剂发生酰化反应,生成化合物26a;或
(2d)化合物23b与酰化剂发生酰化反应,生成化合物26b;
(3a)化合物24a与还原剂及胺基供体发生还原胺化反应,生成化合物25a;或
(3b)化合物24b与还原剂及胺基供体发生还原胺化反应,生成化合物25b;或
(3c)化合物24b与还原剂及R1ONH2或其盐发生还原胺化反应,生成化合物25c;或
(3d)化合物24a与单保护胺PG3NH2或双保护胺PG3NHPG3发生还原胺化反应,生成化合物28a1或28a2;或
(3e)化合物24b与单保护胺PG3NH2或双保护胺PG3NHPG3发生还原胺化反应,生成化合物28b1或28b2;
其中,
R1为THP-、TBS-、甲基或氢;
PG3选自叔丁氧羰基、苄氧羰基、邻苯二甲酰基、三氯乙酰基或邻硝基苯磺酰基;
(4)化合物25c发生还原反应,生成化合物25b;
(5a)化合物26a与叠氮化试剂发生取代反应,生成化合物27a;或
(5b)化合物26b与叠氮化试剂发生取代反应,生成化合物27b;
(6a)化合物27a发生还原反应,生成化合物25a;或
(6b)化合物27b发生还原反应,生成化合物25b;
(7a)化合物25a与酰化剂PG3Cl或PG3OPG3发生酰化反应,生成化合物28a1或28a2;或
(7b)化合物25b与酰化剂PG3Cl或PG3OPG3发生酰化反应,生成化合物28b1或28b2;
(8a)化合物28a1或28a2发生氧化反应,分别生成化合物29a或29b;或
(8b)化合物28b1或28b2发生氧化反应,分别生成化合物29a或29b;
(9)化合物29a或29b发生还原胺化反应,分别生成化合物30a或30b;
(10)化合物30a或30b发生氢化反应、或者亲核脱保护反应、或者碱性脱保护反应,或者还原脱保护反应,生成化合物1。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610802433.8A CN107793389B (zh) | 2016-09-05 | 2016-09-05 | 手性四氢吡喃衍生物及其制备与用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610802433.8A CN107793389B (zh) | 2016-09-05 | 2016-09-05 | 手性四氢吡喃衍生物及其制备与用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107793389A CN107793389A (zh) | 2018-03-13 |
CN107793389B true CN107793389B (zh) | 2021-06-29 |
Family
ID=61530049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610802433.8A Expired - Fee Related CN107793389B (zh) | 2016-09-05 | 2016-09-05 | 手性四氢吡喃衍生物及其制备与用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107793389B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4440927A (en) * | 1981-06-19 | 1984-04-03 | Merck & Co., Inc. | Process for preparing inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase via a chiral synthon |
CN101130515A (zh) * | 2006-08-24 | 2008-02-27 | 中国科学院上海药物研究所 | 取代-1h-吲哚类化合物、其制备方法、其应用及其药物组合物 |
WO2013003249A1 (en) * | 2011-06-29 | 2013-01-03 | Merck Sharp & Dohme Corp. | Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor |
CN105315248A (zh) * | 2014-06-26 | 2016-02-10 | 成都中医药大学 | 一种四氢吡喃醇系列手性化合物及其合成方法和用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7902376B2 (en) * | 2008-01-23 | 2011-03-08 | Merck Sharp & Dohme Corp. | Process for preparing chiral dipeptidyl peptidase-IV inhibitor intermediates |
-
2016
- 2016-09-05 CN CN201610802433.8A patent/CN107793389B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4440927A (en) * | 1981-06-19 | 1984-04-03 | Merck & Co., Inc. | Process for preparing inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase via a chiral synthon |
CN101130515A (zh) * | 2006-08-24 | 2008-02-27 | 中国科学院上海药物研究所 | 取代-1h-吲哚类化合物、其制备方法、其应用及其药物组合物 |
WO2013003249A1 (en) * | 2011-06-29 | 2013-01-03 | Merck Sharp & Dohme Corp. | Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor |
CN105315248A (zh) * | 2014-06-26 | 2016-02-10 | 成都中医药大学 | 一种四氢吡喃醇系列手性化合物及其合成方法和用途 |
Non-Patent Citations (3)
Title |
---|
DPPIV抑制剂筛选模型的优化与应用;江慧贤等;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20130415(第4期);第E065-10页 * |
Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes;Tesfaye Biftu等;《J. Med. Chem.》;20140324;第57卷;第3205-3212页 * |
Stereoselective and Regioselective Preparation of C-Pentopyranosides and Formal Synthesis of Omariglipti;Tongchao Liu等;《Eur. J. Org. Chem.》;20161107;第5624-5628页 * |
Also Published As
Publication number | Publication date |
---|---|
CN107793389A (zh) | 2018-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008518901A (ja) | インダゾール化合物を調製するための方法 | |
RU2669701C2 (ru) | Производные пиперидина в качестве антагонистов рецептора орексина | |
KR101520337B1 (ko) | 이민 수소화에 의한 2,2-디플루오로에틸아민 유도체의 제조방법 | |
CN106068271B (zh) | 2′-取代-2,2′-脱水尿苷或2′-取代-2,2′-脱水胞苷化合物及其制备方法和用途 | |
CZ20031209A3 (cs) | Způsob glykosidace indolokarbazolu | |
JP3173602B2 (ja) | エンイン誘導体の新規製造中間体及びその製造法 | |
KR102477924B1 (ko) | 인돌 카르복스아미드 화합물을 제조하는 방법 | |
CN110483549B (zh) | 一种硝基咪唑吡喃类抗结核药物的制备方法 | |
WO2008090046A1 (en) | Alternate process for preparing 3,5-di-omicron-acyl-2-fluoro-2-c-methyl-d-ribono-gamma-lactone | |
CN107793389B (zh) | 手性四氢吡喃衍生物及其制备与用途 | |
WO2004106352A1 (ja) | アルドヘキソピラノース中間体の製造法 | |
JP6173427B2 (ja) | α−ハロテトラアシルグルコースの製造方法 | |
JPH0570474A (ja) | 9−デオキソ−9(z)−ヒドロキシイミノエリスロマイシンaおよびそのo−誘導体 | |
KR20060055440A (ko) | 리보푸라노스 유도체의 제조방법 | |
CN112028816B (zh) | 一种取代异吲哚啉的合成方法 | |
Popsavin et al. | Synthesis of highly cytotoxic tiazofurin mimics bearing a 2, 3-anhydro function in the furanose ring | |
JP7309725B2 (ja) | 2環性ヘテロ芳香環誘導体 | |
JP7379415B2 (ja) | カテキン抱合体の製造方法 | |
CN109970673B (zh) | 帕瑞昔布钠杂质的制备方法 | |
Fujii et al. | Synthesis and reactions of 3-and 8-ethynyl-1-azaazulenes | |
EP2049558B1 (en) | Naphthalene 2-carboxylate derivative useful for synthesizing gemcitabine and a method for preparing the same | |
US20230096670A1 (en) | Intermediate useful for synthesis of sglt inhibitor and method for preparing sglt inhibitor using same | |
CN107304179B (zh) | 一种lcz696中间体的合成方法 | |
Merlani et al. | Synthesis of 17 α-amino-5 α-androst-2-ene from epiandrosterone | |
KINOSHITA et al. | Pyrimidine Derivatives. V. Synthesis and Nucleophilic Reactions of 5-Bromo-6-bromomethy1-1-(2-bromoethyl and 2-bromopropy1)-3-methyl-2, 4 (1H, 3H)-pyrimidinedione |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210629 |